Tags

Type your tag names separated by a space and hit enter

Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors.
Clin Nutr 2013; 32(5):686-96CN

Abstract

BACKGROUND & AIMS

The study examined the value of n-3 LC-PUFA-enriched yogurt as means of improving cardiovascular health.

DESIGN

Fifty three mildly hypertriacylglycerolemic subjects (TAG ≥ 1.7 mmol/L) participated in a randomized, placebo-controlled, double-blind, parallel designed study. The subjects consumed 1) control yoghurt; 2) yoghurt enriched with 0.8 g n-3 LC-PUFA/d; or 3) yoghurt enriched with 3 g n-3 LC-PUFA/d for a period of 10 wks. Blood samples were taken at the beginning and the end of the study period.

RESULTS

Following daily intake of 3 g n-3 LC-PUFA for 10 weeks, n-3 LC-PUFA levels increased significantly in plasma and red blood cells (RBC) with concomitant increase in the EPA-derived mediators (PGE₃, 12-, 15-, 18-HEPE) in plasma whilst cardiovascular risk factors such as HDL, TAG, AA/EPA ratio, and n-3 index were improved (P < 0.05); the decrease of TAG and increase in HDL were associated with the CD36 genotype.

CONCLUSION

The observed increase of n-3 LC-PUFA in RBC and plasma lipids due to intake of n-3 LC-PUFA enriched yoghurt resulted in a reduction of cardiovascular risk factors and inflammatory mediators showing that daily consumption of n-3 PUFA enriched yoghurt can be an effective way of supplementing the daily diet and improving cardiovascular health.

Authors+Show Affiliations

Department of Nutritional Physiology, Institute of Nutrition, Friedrich Schiller University of Jena, Dornburger Str. 24, D-07743 Jena, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

23332800

Citation

Dawczynski, Christine, et al. "Randomized Placebo-controlled Intervention With N-3 LC-PUFA-supplemented Yoghurt: Effects On Circulating Eicosanoids and Cardiovascular Risk Factors." Clinical Nutrition (Edinburgh, Scotland), vol. 32, no. 5, 2013, pp. 686-96.
Dawczynski C, Massey KA, Ness C, et al. Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors. Clin Nutr. 2013;32(5):686-96.
Dawczynski, C., Massey, K. A., Ness, C., Kiehntopf, M., Stepanow, S., Platzer, M., ... Jahreis, G. (2013). Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors. Clinical Nutrition (Edinburgh, Scotland), 32(5), pp. 686-96. doi:10.1016/j.clnu.2012.12.010.
Dawczynski C, et al. Randomized Placebo-controlled Intervention With N-3 LC-PUFA-supplemented Yoghurt: Effects On Circulating Eicosanoids and Cardiovascular Risk Factors. Clin Nutr. 2013;32(5):686-96. PubMed PMID: 23332800.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors. AU - Dawczynski,Christine, AU - Massey,Karen A, AU - Ness,Christina, AU - Kiehntopf,Michael, AU - Stepanow,Stefanie, AU - Platzer,Matthias, AU - Grün,Michael, AU - Nicolaou,Anna, AU - Jahreis,Gerhard, Y1 - 2012/12/28/ PY - 2012/07/19/received PY - 2012/11/22/revised PY - 2012/12/05/accepted PY - 2013/1/22/entrez PY - 2013/1/22/pubmed PY - 2014/4/17/medline KW - 17S-HDHA KW - 17S-hydroxy-docosahexaenoic acid KW - AA KW - ALA KW - BF(3) KW - Blood lipids KW - CAD KW - CHD KW - CLA KW - COX KW - CRP KW - CYP450 KW - Cytokines KW - DGLA KW - DHA KW - Dairy products KW - EPA KW - Eicosanoids KW - FAME KW - FFP KW - Food Frequency Protocol KW - HDL KW - HEPE KW - HETE KW - HETrE KW - HODE KW - IFN KW - IL KW - LA KW - LDL KW - LOX KW - LPS KW - LT KW - MUFA KW - OC KW - PG KW - PL KW - PPAR KW - RBC KW - RRs KW - Rv KW - SFA KW - SNPs KW - SREBPs KW - TAG KW - TBX KW - TC KW - TLC KW - TNFα KW - VLDL KW - arachidonic acid KW - boron trifluoride KW - c-reactive protein KW - conjugated linoleic acids KW - coronary artery diseases KW - coronary heart disease KW - cyclooxygenase KW - cytochrome P450 monooxygenases KW - dihomo-γ-linolenic acid KW - docosahexaenoic acid KW - eicosapentaenoic acid KW - fatty acid methyl esters KW - high density lipoprotein KW - hydroxy-eicosapentaenoic acid KW - hydroxy-eicosatetraenoic acid KW - hydroxy-eicosatrienoic acid KW - hydroxy-octadecaenoic acid KW - interferon KW - interleukin KW - leukotrienes KW - linoleic acid KW - lipopolysaccharide KW - lipoxygenase KW - low density lipoprotein KW - monounsaturated fatty acids KW - n-3 LC-PUFA KW - n-3 long-chain polyunsaturated fatty acids KW - osteoclast KW - peroxisome proliferator activated receptor KW - plasma lipids KW - prostaglandins KW - red blood cells KW - relative ratios KW - resolvin KW - saturated fatty acids KW - single nucleotide polymorphisms KW - sterol regulatory element-binding proteins KW - thin layer chromatography KW - thromboxanes KW - total cholesterol KW - triacylglycerides KW - tumor necrosis factor alpha KW - very low density lipoprotein KW - α-linolenic acid SP - 686 EP - 96 JF - Clinical nutrition (Edinburgh, Scotland) JO - Clin Nutr VL - 32 IS - 5 N2 - BACKGROUND & AIMS: The study examined the value of n-3 LC-PUFA-enriched yogurt as means of improving cardiovascular health. DESIGN: Fifty three mildly hypertriacylglycerolemic subjects (TAG ≥ 1.7 mmol/L) participated in a randomized, placebo-controlled, double-blind, parallel designed study. The subjects consumed 1) control yoghurt; 2) yoghurt enriched with 0.8 g n-3 LC-PUFA/d; or 3) yoghurt enriched with 3 g n-3 LC-PUFA/d for a period of 10 wks. Blood samples were taken at the beginning and the end of the study period. RESULTS: Following daily intake of 3 g n-3 LC-PUFA for 10 weeks, n-3 LC-PUFA levels increased significantly in plasma and red blood cells (RBC) with concomitant increase in the EPA-derived mediators (PGE₃, 12-, 15-, 18-HEPE) in plasma whilst cardiovascular risk factors such as HDL, TAG, AA/EPA ratio, and n-3 index were improved (P < 0.05); the decrease of TAG and increase in HDL were associated with the CD36 genotype. CONCLUSION: The observed increase of n-3 LC-PUFA in RBC and plasma lipids due to intake of n-3 LC-PUFA enriched yoghurt resulted in a reduction of cardiovascular risk factors and inflammatory mediators showing that daily consumption of n-3 PUFA enriched yoghurt can be an effective way of supplementing the daily diet and improving cardiovascular health. SN - 1532-1983 UR - https://www.unboundmedicine.com/medline/citation/23332800/Randomized_placebo_controlled_intervention_with_n_3_LC_PUFA_supplemented_yoghurt:_effects_on_circulating_eicosanoids_and_cardiovascular_risk_factors_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0261-5614(12)00283-X DB - PRIME DP - Unbound Medicine ER -